Anti-IL5 therapy for asthma and beyond
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nair, 2013, What is an “eosinophilic phenotype” of asthma?, J Allergy Clin Immunol, 132, 81, 10.1016/j.jaci.2013.05.007
Rothenberg, 2006, The Eosinophil, Annu Rev Immunol, 24, 147, 10.1146/annurev.immunol.24.021605.090720
Hargreave, 1999, Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 160, S53, 10.1164/ajrccm.160.supplement_1.14
Vaglio, 2013, Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art, Allergy, 68, 261, 10.1111/all.12088
Busse, 2010, A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma, J Allergy Clin Immunol, 125, 803, 10.1016/j.jaci.2009.11.048
Gleich, 2000, Mechanisms of eosinophil-associated inflammation, J Allergy Clin Immunol, 105, 651, 10.1067/mai.2000.105712
Foster, 1996, Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model, J Exp Med, 183, 195, 10.1084/jem.183.1.195
Bousquet, 1990, Eosinophilic inflammation in asthma, New Engl J Med, 323, 1033, 10.1056/NEJM199010113231505
Shi, 1998, Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics, Am J Respir Crit Care Med, 157, 204, 10.1164/ajrccm.157.1.9703027
Hambly, 2014, Monoclonal antibodies for the treatment of refractory asthma, Curr Opin Pulm Med, 20, 87, 10.1097/MCP.0000000000000007
Pelaia, 2012, The potential of biologics for the treatment of asthma, Nat Rev Drug Discov, 11, 958, 10.1038/nrd3792
Garcia, 2013, Anti-interleukin-5 therapy in severe asthma, Eur Respir Rev, 22, 251, 10.1183/09059180.00004013
Lee, 2010, Eosinophils in health and disease: the LIAR hypothesis, Clin Exper Allergy, 40, 563, 10.1111/j.1365-2222.2010.03484.x
Arron, 2013, Chapter One - Redefining Approaches to Asthma: Developing Targeted Biologic Therapies, 1, 10.1016/B978-0-12-404717-4.00001-9
Leckie, 2000, Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response, Lancet, 356, 2144, 10.1016/S0140-6736(00)03496-6
Büttner, 2003, Monoclonal anti-interleukin‒5 treatment suppresses eosinophil but not T‒cell functions, Eur Respir J, 21, 799, 10.1183/09031936.03.00027302
Kips, 2003, Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma, Am J Respir Crit Care Med, 167, 1655, 10.1164/rccm.200206-525OC
Flood-Page, 2003, Eosinophil’s role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway, Am J Respir Crit Care Med, 167, 199, 10.1164/rccm.200208-789OC
Flood-Page, 2007, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma, Am J Respir Crit Care Med, 176, 1062, 10.1164/rccm.200701-085OC
Nair, 2009, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia, New Engl J Med, 360, 985, 10.1056/NEJMoa0805435
Haldar, 2009, Mepolizumab and exacerbations of refractory eosinophilic asthma, New Engl J Med, 360, 973, 10.1056/NEJMoa0808991
Pavord, 2012, Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, 380, 651, 10.1016/S0140-6736(12)60988-X
Castro, 2011, Reslizumab for poorly controlled, eosinophilic asthma, Am J Respir Crit Care Med, 184, 1125, 10.1164/rccm.201103-0396OC
Busse, 2010, Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma, J Allergy Clin Immunol, 125, 1237, 10.1016/j.jaci.2010.04.005
Laviolette, 2013, Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia, J Allergy Clin Immunol, 132, 1086, 10.1016/j.jaci.2013.05.020
Mario, 2014, Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma
Ortega, 2014, Mepolizumab treatment in patients with severe eosinophilic asthma, N Engl J Med, 371, 1198, 10.1056/NEJMoa1403290
Bel, 2014, Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, N Engl J Med, 371, 1189, 10.1056/NEJMoa1403291
Corren, 2014, A randomized phase 3 study f reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
Bjermer, 2014, A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils
Nair, 2014, Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma, N Engl J Med, 371, 1249, 10.1056/NEJMe1408614
Gevaert, 2003, Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis, Allergy, 58, 371, 10.1034/j.1398-9995.2003.00110.x
Ghazi, 2011, Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma, Expert Opin Biol Ther, 12, 113, 10.1517/14712598.2012.642359
Nair, 2012, How to diagnose and phenotype asthma, Clin Chest Med, 33, 445, 10.1016/j.ccm.2012.05.003
Gauvreau, 2008, Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses, Am J Respir Crit Care Med, 177, 952, 10.1164/rccm.200708-1251OC
Neighbour, 2014, Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial, Clin Exper Allergy, 44, 508, 10.1111/cea.12244
Guy, 2013, Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma, Nat Med, 19, 977, 10.1038/nm.3300
Licona-Limon, 2013, TH2, allergy and group 2 innate lymphoid cells, Nat Immunol, 14, 536, 10.1038/ni.2617
Yu, 2014, Innate lymphoid cells and asthma, J Allergy Clin Immunol, 133, 943, 10.1016/j.jaci.2014.02.015
Walker, 2013, Development and function of group 2 innate lymphoid cells, Curr Opin Immunol, 25, 148, 10.1016/j.coi.2013.02.010
Allakhverdi, 2007, Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells, J Exp Med, 204, 253, 10.1084/jem.20062211
Moore, 2002, IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK, Am J Physiol Lung Cell Mol Physiol, 282, L847, 10.1152/ajplung.00245.2001
Matsukura, 2001, Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism, Am J Respir Cell Mol Biol, 24, 755, 10.1165/ajrcmb.24.6.4351
Punia, 2012, Interleukin-4 and interleukin-13 prime migrational responses of haemopoietic progenitor cells to stromal cell-derived factor-1α, Clin Exp Allergy, 42, 255, 10.1111/j.1365-2222.2011.03889.x
Roma S, Kayla M, Anam I, Navneet P, Steven GS: Thymic stromal lymphopoietin (TSLP) and IL-33 prime the migrational responses of eosinophil-lineage committed progenitor cells. In A14 Interleukin-33: A Pivotal Mediator for Crosstalk between Innate and Adaptive Inflammatory Responses in the Lung. American Thoracic Society; 2013:A1005–A1005.
Hui, 2011, Effects of thymic stromal lymphopoietin on cord blood progenitor cell differentiation and hemopoietic cytokine receptors expression, Allergy Asthma Clin Immunol, 7, A24, 10.1186/1710-1492-7-S2-A24
Pavord, 1999, Non-eosinophilic cor ticosteroid unresponsive asthma, Lancet, 353, 2213, 10.1016/S0140-6736(99)01813-9
Fanat, 2009, Human airway smooth muscle promotes eosinophil differentiation, Clin Exp Allergy, 39, 1009, 10.1111/j.1365-2222.2009.03246.x
Sehmi, 2009, Allergy and the bone marrow: transmigration pathways of hemopoietic progenitor cells from the bone marrow, 421
Kim, 1999, Immunolocalization of CD34 in nasal polyposis. Effect of topical corticosteroids, Am J Respir Cell Mol Biol, 20, 388, 10.1165/ajrcmb.20.3.3060
Cameron, 2000, Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor, J Immunol, 164, 1538, 10.4049/jimmunol.164.3.1538
Wenzel, 2013, Dupilumab in Persistent Asthma with Elevated Eosinophil Levels, New Engl J Med, 368, 2455, 10.1056/NEJMoa1304048
Garrett, 2004, Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes, J Allergy Clin Immunol, 113, 115, 10.1016/j.jaci.2003.10.049
Rothenberg, 2008, Treatment of patients with the hypereosinophilic syndrome with mepolizumab, New Engl J Med, 358, 1215, 10.1056/NEJMoa070812
Roufosse, 2010, Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome, J Allergy Clin Immunol, 126, 828, 10.1016/j.jaci.2010.06.049
Kim, 2010, Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome, J Allergy Clin Immunol, 125, 1336, 10.1016/j.jaci.2010.03.028
Moosig, 2011, Targeting interleukin-5 in refractory and relapsing churg–strauss syndrome, Ann Intern Med, 155, 341, 10.7326/0003-4819-155-5-201109060-00026
Brightling CE, Bleecker ER, Panettieri RA, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R: Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014, Sept 5 2014, published online.
Kahn, 2010, Sustained response to mepolizumab in refractory Churg-Strauss syndrome, J Allergy Clin Immunol, 125, 267, 10.1016/j.jaci.2009.10.014
Dasgupta, 2013, Targeted therapy of bronchitis in obstructive airway diseases, Pharmacol Ther, 140, 213, 10.1016/j.pharmthera.2013.07.001